Enzychem Lifesciences' largest shareholder Nam Yun-hee and 133 others form joint holding agreement for 5.98% stake, aiming to exercise management influence and resume trading
Largest shareholder Nam Yun-hee entered into a joint holding agreement with 133 individual shareholders, newly acquiring a 5.98% stake (5,065,345 shares) for the purpose of exercising management influence.
The stated purpose includes active exercise of voting rights to normalize management, such as filing lawsuits to resume trading, appointing/removing directors, amending the articles of incorporation, and changing capital.
All acquisition funds were self-financed with no debt, indicating low financial burden, but the formation of a large shareholder alliance could raise the possibility of a management dispute.
Nam Yun-hee personally holds 256,840 shares (0.30%), while major holders among special relations include Park Chan-kyung (754,000 shares, 0.89%) and Lee Sang-heon (506,759 shares, 0.60%).
[AI Summary]The joint holding agreement may strengthen minority shareholders' ability to check management, but it also carries the risk of triggering a management dispute, likely increasing stock price volatility.